The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment.

Manuel Lima-Rodrigues,Nuno J. Lamas,Ana Valle-Fernandes,Andrea Cruz,Artur Vieira,Pedro Oliveira,Jorge Pedrosa,António G. Castro,Rui Manuel Reis,Fátima Baltazar,Armando Almeida

The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment.

2010

Manuel Lima-Rodrigues
Nuno J. Lamas
Ana Valle-Fernandes
Andrea Cruz
Artur Vieira
Pedro Oliveira
Jorge Pedrosa
António G. Castro
Rui Manuel Reis
Fátima Baltazar
Armando Almeida

Objective A randomised experimental study was used to evaluate the therapeutic effect of a selective cyclooxygenase-2 (COX-2) inhibitor in neurogenic laryngitis.

Keywords:

Diabetes mellitus
Calcitonin gene-related peptide
Substance P
Laryngitis
Biochemistry
Etoricoxib
Therapeutic effect
Cyclooxygenase
COX-2 inhibitor
Medicine
Anesthesia
Allergy
Rheumatology
Pharmacology
Internal medicine
Neurology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations